Kedrion Biopharma Launches QIVIGY® National Distribution Network for Better Patient Access Kedrion Biopharma has announced the national distribution of QIVIGY, its FDA-approved immunoglobulin therapy, boosting access for patients across various healthcare settings in the U.S.

Kedrion Biopharma Launches QIVIGY® National Distribution Network for Better Patient Access #United_States #Fort_Lee #Kedrion_Biopharma #Immunoglobulin #QIVIGY

Kedrion Biopharma Celebrates FDA Approval of QIVIGY® for Adults with Primary Immunodeficiency Kedrion Biopharma's new IVIG treatment, QIVIGY®, has received FDA approval to aid adults with Primary Humoral Immunodeficiency, marking a significant milestone for the company.

Kedrion Biopharma Celebrates FDA Approval of QIVIGY® for Adults with Primary Immunodeficiency #United_States #FDA_Approval #Fort_Lee #Kedrion_Biopharma #QIVIGY